商务合作
动脉网APP
可切换为仅中文
Expansion into regenerative medicine is a strategic move to broaden treatment possibilities, address unmet needs and shape the future of veterinary care
进军再生医学领域是一项战略举措,旨在拓展治疗可能性、满足尚未被满足的需求,并塑造兽医护理的未来。
BOSTON
波士顿
,
,
Nov. 17, 2026
2026年11月17日
/PRNewswire/ -- Dechra, a global leader in veterinary specialty care, today completed its acquisition of Gallant Pet Inc (Gallant), a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets. Representing another milestone on Dechra's transformation journey, the expansion into regenerative medicine has the potential to broaden treatment options for complex conditions, address significant unmet needs and help shape the future of veterinary care through a new therapeutic platform.
/美通社/ -- 全球兽医专科护理领域的领导者德克拉(Dechra)今日完成了对美国动物健康生物技术公司Gallant Pet Inc(以下简称“Gallant”)的收购。Gallant致力于开创面向宠物的即用型间充质基质细胞(MSC)疗法。此次收购标志着德克拉在转型征程中又迈出一个重要里程碑。通过进军再生医学领域,德克拉有望拓宽复杂疾病的治疗选择,满足尚未被充分满足的重大需求,并借助全新的治疗平台塑造兽医护理的未来。
.
。
Continue Reading
继续阅读
Dechra Acquires Gallant
Dechra 收购 Gallant
These ready-to-use, MSC therapies are designed to work with the body's natural biological processes. By bringing this first-of-its-kind therapy into the Dechra portfolio, the company is advancing a new therapeutic platform designed to treat chronic and complex conditions in pets.
这些即用的间充质干细胞(MSC)疗法旨在与机体的自然生物过程协同作用。通过将这种首创疗法纳入德克拉(Dechra)的产品组合,该公司正在推进一个全新的治疗平台,该平台专为治疗宠物的慢性及复杂病症而设计。
'This acquisition is a strategic investment in expanding what's possible in veterinary care,' said Dr. Cathy Knupp, Chief Scientific Officer, Dechra. 'By combining our specialty animal health expertise, global reach and established veterinary relationships with Gallant's scientific innovation and regenerative medicine platform, we're creating a strong foundation to bring new treatment options to veterinarians and their patients.'.
“此次收购是对拓展兽医护理可能性的一项战略性投资,”德克拉首席科学官凯西·克努普博士表示。“通过将我们在专业动物健康领域的专业知识、全球布局以及成熟的兽医合作关系,与加兰特的科学创新和再生医学平台相结合,我们正为向兽医及其患者提供新的治疗选择奠定坚实基础。”
Designed to support multiple therapies across different conditions and species, Gallant's pipeline creates opportunities for continued innovation and development as well as a platform with the potential to establish regenerative medicine as a valued standard in veterinary practice.
Gallant的产品管线旨在支持针对不同病症和物种的多种疗法,为持续创新与开发创造机遇,并搭建一个有望将再生医学确立为兽医实践中有价值标准的技术平台。
'Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need,' said Dr. Linda Black, CEO of Gallant. 'Dechra understood that vision from the start. We are thrilled to begin this new chapter as part of Dechra who shares our dedication to science and heart.
“Gallant 的创立基于一个大胆的理念,即让所有有需要的宠物都能获得再生医学治疗,”Gallant 首席执行官琳达·布莱克博士表示。“Dechra 从一开始就理解这一愿景。我们很高兴作为 Dechra 的一员开启这一新篇章,他们与我们一样,秉持对科学与仁心的坚定承诺。”
I'm incredibly proud of the team that got us here, and excited to keep pioneering together.'.
我为带领我们取得今日成就的团队感到无比自豪,并期待继续携手开拓前行。
The first innovation from the pipeline is anticipated as early as 2027. The transaction has been finalized and both parties have agreed that the terms of the transaction will remain confidential.
管线中的首个创新产品预计最早于2027年问世。该交易已尘埃落定,双方均同意对交易条款保密。
About Dechra
关于 Dechra
Dechra is a global leader in veterinary specialty care, dedicated to making a difference in animal health through purpose-built solutions and trusted partnerships that support veterinarian professionals, pet parents, horse owners, and the animals they care for. Our difference makes a difference. To learn more, visit .
德克拉是全球兽医专科护理领域的领导者,致力于通过专为满足需求而设计的解决方案和值得信赖的合作伙伴关系,为兽医专业人士、宠物主人、马匹所有者以及他们所照料的动物提供支持,从而改善动物健康。我们的与众不同,造就非凡影响。欲了解更多信息,请访问。
dechra‐us.com
dechra-us.com
.
。
About Gallant
关于 Gallant
Gallant is an animal health biotechnology company creating opportunity in veterinary care with a pipeline of off-the-shelf, ready-to-use stromal cell therapies targeting the root cause of disease in pets. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible — moving beyond symptom management to restoring health at the source.
Gallant 是一家动物健康生物技术公司,通过提供一系列现成、可直接使用的间充质干细胞疗法,瞄准宠物疾病的根本病因,为兽医护理领域创造新机遇。Gallant 由兽医再生医学领域的先驱者领导,团队在产品开发、制造和商业化方面拥有深厚专长,致力于让再生医学惠及更多用户——超越单纯的症状管理,从源头恢复健康。
Learn more at .
了解更多,请访问。
www.gallant.com
www.gallant.com
.
。
Media Contact:
媒体联系人:
Lauren Dorsch
劳伦·多尔施
VP, Corporate Affairs and Commercial Communications, Dechra
德赫拉公司事务与商业传播副总裁
913-914-6903
913-914-6903
[email protected]
[email protected]
SOURCE Dechra
来源:Dechra